News >

FDA Approves Obinutuzumab for Follicular Lymphoma

Jason M. Broderick @jasoncology
Published: Friday, Feb 26, 2016

Dr. Sandra Horning

Sandra Horning, MD

The FDA approved obinutuzumab (Gazyva) plus bendamustine followed by obinutuzumab alone for the treatment of patients with follicular lymphoma who relapsed after, or are refractory to, a rituximab-containing regimen, according to Genentech, the manufacturer of the anti-CD20 agent.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x